中文摘要：

当药抵抗看起来是在 monotherapy 的越来越多的 anticancer 药的一个不可避免的问题时，联合药治疗成为了一个繁荣的方法减少管理的全部的药剂量以及克服癌房间的药抵抗。Curcumin，考虑了作为 chemoresistance 的一块压板根据它的多重反肿瘤的机制在癌症治疗拥有 multifaceted 角色，能显著地便于它的反癌症功能并且改进经由联合用法与的治疗学的效果许多有不同反应机制的另外的药。探索这可能性，四反癌症都拥有药抵抗问题的某个度的化学疗法的代理人，包括三个酷氨酸 kinase 禁止者( erlotinib ， sunitinib 和 sorafenib )，那对不同房间小径和典型 anticancer 药 doxorubicin 正在起作用，个别地与 curcumin 被相结合在 vitro 并且在 vivo 检验 synergistic 反肿瘤效果。结果表明在 0.46 的臼齿的比率与 curcumin 相结合的 sunitinib 在 vitro 产出大多数有势力 synergistic 效果，并且因此为进一步的动物评估被选择。为了推进，提高 anticancer 效果，牛的浆液白朊(BSA ) nanoparticles 作为一个搬运人被利用在 situ 交付选择的药联合。在证实的 vivo 调查结果初步我们能由我们的途径在测试动物为延长时间时期维持类似的注射的药比率的假设，从而最大化还最小化这些药的毒性的治疗学的力量。这个工作能在联合药治疗和实现上开创一条新大街如此的药的临床的用途。

英文摘要：

While drug resistance appears to be an inevitable problem of an increasing number of anticancer drugs in monotherapy, combination drug therapy has become a prosperous method to reduce the administered total drug dosages as well as overcome the drug resistance of carcinoma cells. Curcumin, considered to possess multi- faceted roles in cancer treatment according to its multiple anti-neoplastic mechanisms as a depressor of chemo- resistance, can significantly facilitate its anti-cancer functions and improve therapeutic effects via combination usage with a variety of other drugs with different reaction mechanisms. To explore this possibility, four anti-cancer chemotherapeutic agents that all possess a certain degree of drug resistance problems, including three tyrosine kinase inhibitors （erlotinib, sunitinib and sorafenib） that are acting on different cell pathways and a typical anticancer drug doxorubicin, were combined with curcumin individually to examine the synergistic anti-tumor effect both in vitro and in vivo. Results revealed that sunitinib combined with curcumin at the molar ratio of 0.46 yielded the most potent synergistic effect in vitro, and was therefore chosen for further animal evaluation. To further enhance the anti- cancer effect, bovine serum albumin （BSA） nanoparticles were utilized as a carrier to deliver the selected drug combination in situ. Preliminary in vivo findings confirmed our hypothesis of being able to maintain a similar injected drug ratio for prolonged time periods in tested animals by our approach, thereby maximizing the therapeutic potency yet minimizing the toxicity of these drugs. This work could open up a new avenue on combination drug therapy and realization the clinical utility of such drugs.